Evaluation of Undifferentiated Pancreatic Disorder
A standardized diagnostic approach for an undifferentiated pancreatic disorder is based on (1) high-quality cross-sectional imaging for anatomic characterization and staging and (2) endoscopic ultrasound–guided tissue acquisition when a diagnosis cannot be established noninvasively. ASGE solid pancreatic neoplasia guideline (EUS role)
Initial Imaging and Problem Definition
Contrast-enhanced pancreas-protocol CT is recommended as the initial anatomic test to characterize a pancreatic mass lesion and assess resectability and metastatic disease. ASGE solid pancreatic neoplasia guideline (EUS role)
MRI with MRCP is recommended when CT is nondiagnostic or when additional ductal anatomy and character are needed. [1]
Risk Stratification for Malignancy and Nonmalignant Mimics
The diagnostic work-up should explicitly consider pancreatic adenocarcinoma and major nonmalignant mimics such as autoimmune pancreatitis, neuroendocrine tumors, and other solid neoplasms. [1]
Serum CA 19-9 and cross-sectional imaging findings should be used to support pretest probability, but imaging alone is not considered a definitive substitute for tissue diagnosis in most undifferentiated cases. [1]
Endoscopic Ultrasound–Guided Tissue Acquisition
Endoscopic ultrasound (EUS) with guided sampling is recommended when noninvasive testing does not establish a diagnosis and when histologic confirmation is required to guide management. ASGE solid pancreatic neoplasia guideline (EUS role)
EUS-guided tissue acquisition is favored over CT-guided biopsy in patients with nonmetastatic disease because diagnostic yield is generally higher and safety is improved. NCCN principles of diagnosis and staging excerpt (version 3.2024)
Sampling Strategy in Solid Pancreatic Lesions
EUS-guided fine-needle aspiration (EUS-FNA) and EUS-guided fine-needle biopsy (EUS-FNB) are both used for pancreatic solid lesions, with the selection based on local expertise, lesion characteristics, and target adequacy requirements. [2]
EUS specimen adequacy and diagnostic performance should be tracked as quality metrics, including diagnostic rate and malignancy sensitivity. [2]
Monotherapy Versus Combination Diagnostic Pathways
When imaging establishes a clear diagnosis and management would not change, invasive confirmation may be avoided in selected circumstances; radiologic suspicion alone is not considered sufficient when treatment depends on histology. [1]
When imaging remains indeterminate, the diagnostic pathway should combine EUS-based tissue acquisition with targeted evaluation of specific competing etiologies that alter therapy. ASGE solid pancreatic neoplasia guideline (EUS role)
Treatment-Relevant Diagnostic Timing
EUS-based tissue acquisition should be performed promptly after initial cross-sectional imaging when diagnosis is uncertain, because staging and resectability assessment are already underway and histology is often required before definitive treatment planning. NCCN principles of diagnosis and staging excerpt (version 3.2024)
Common Pitfalls to Avoid
Relying on cross-sectional imaging without tissue confirmation in undifferentiated cases can lead to misdiagnosis because radiologic characterization may not correlate with histology. [1]
Incomplete or inadequately performed EUS sampling can reduce diagnostic accuracy, so quality indicators for diagnostic rate and sensitivity should be met in practice. [2]